Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
Sponsor: Abramson Cancer Center at Penn Medicine
A observational or N/A phase clinical study on Breast Cancer and Cardiotoxicity, this trial is ongoing. The trial is conducted by Abramson Cancer Center at Penn Medicine and has accumulated 11 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Enrolling By Invitation
-
Feb 2025 — Feb 2026 [monthly]
Enrolling By Invitation
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jan 2025 — Feb 2025 [monthly]
Not Yet Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Not Yet Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Not Yet Recruiting
▶ Show 6 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting
-
May 2024 — Jun 2024 [monthly]
Not Yet Recruiting
-
Apr 2024 — May 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Abramson Cancer Center at Penn Medicine
For direct contact, visit the study record on ClinicalTrials.gov .